Protocol summary

Study aim
Evaluating the effect of melatonin as an adjuvant therapy on the mortality and the duration of mechanical ventilation in ICU admitted COVID 19 patients
Design
Permuted block randomization will be used to randomize patients in melatonin and control group. this is an open labeled study without blinding (phase 1 trial with 33 patients)
Settings and conduct
66 intubated patients with COVID-19 infection who admitted to the Intensive care unit (Baharloo hospital, Tehran) were randomized to receive either 21mg melatonin or placebo for 5 days. Patients Main outcomes are the duration of mechanical ventilation requirements, and mortality.
Participants/Inclusion and exclusion criteria
Inclusion critria: all COVID19 patients more than 18 years old at first day of intubation Excusion critria: hepatic failure- liver enzyme more than 5 time of upper normal limit
Intervention groups
Patients will be randomized to receive either melatonin or placebo
Main outcome variables
Main outcomes are the duration of mechanical ventilation requirements, and mortality.

General information

Reason for update
Acronym
BMCOVID
IRCT registration information
IRCT registration number: IRCT20210225050495N1
Registration date: 2021-10-01, 1400/07/09
Registration timing: registered_while_recruiting

Last update: 2021-10-01, 1400/07/09
Update count: 0
Registration date
2021-10-01, 1400/07/09
Registrant information
Name
Hadiseh Hosamirudsari
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 6585 0011
Email address
h-hosami@sina.tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-08-11, 1400/05/20
Expected recruitment end date
2022-02-09, 1400/11/20
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluating the Effect of melatonin on mechanically ventilated COVID 19 patients in Intensive care unit
Public title
Evaluating the Effect of melatonin on mechanically ventilated COVID 19 patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
all covid-19 patients admitted to the ICU Mechanically ventilated patients within the first 24 hours of intubation
Exclusion criteria:
liver enzyme more than 5 times of normal upper limit
Age
From 18 years old
Gender
Both
Phase
2-3
Groups that have been masked
No information
Sample size
Target sample size: 66
Randomization (investigator's opinion)
Randomized
Randomization description
patients were randomized using Allocation random software (version 2.0) trough random block sizes of 4 and 6 with an allocation ratio of 1:1, to receive either melatonin or placebo. this is an open labeled study without blinding
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

1

Registry name
Tehran university of medical sciences
Secondary trial Id
IR.TUMS.VCR.REC.1399.159
Registration date
2020-04-02, 1399/01/14

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Tehran University of Medical Sciences
Street address
Baharloo hospital, Behdari avenue, Rah-Ahan square
City
Tehran
Province
Tehran
Postal code
12299
Approval date
2020-04-05, 1399/01/17
Ethics committee reference number
IR.TUMS.VCR.REC.1399.159

Health conditions studied

1

Description of health condition studied
critical COVID19
ICD-10 code
U07.1 COVI
ICD-10 code description
U07.1 COVID-19, virus identified

Primary outcomes

1

Description
In ICU Mortality Percent
Timepoint
At the end of the study
Method of measurement
The Number of Alive patients at the end of the study in each group

2

Description
the duration of the mechanical ventilation
Timepoint
at the end of the study
Method of measurement
Calculating the total days of mechanical ventilation

Secondary outcomes

empty

Intervention groups

1

Description
Patients in melatonin group will receive 21mg of melatonin (Razak) every night for 5 days through nasogastric tubr
Category
Treatment - Drugs

2

Description
Control group: Placebo group will receive placebo produced by Razak Company, every night for 5 nights
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Baharloo Hospital
Full name of responsible person
Hadiseh Hosamirudsari
Street address
Baharloo hospital, Railway square, Behdari Ave,Tehrannue
City
Tehran
Province
Tehran
Postal code
139973111
Phone
+98 21 5565 8500
Fax
+98 21 5564 8189
Email
baharloo@sina.tums.ac.ir
Web page address
https://baharloo.tums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Mohammadali Sahraian
Street address
Baharloo Hospital,Rah ahan Square, Behdari Avenue,Tehran, Rah ahan Square
City
Tehran
Province
Tehran
Postal code
139973111
Phone
+98 21 5565 8500
Fax
+98 21 5564 8189
Email
h-hosami@sina.tums.ac.ir
Web page address
https://bahaloo.tums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Hadiseh Hosamirudsari
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Infectious diseases
Street address
Baharloo Hospital- Behdari Street- Rah Ahan Square
City
Tehran
Province
Tehran
Postal code
139973111
Phone
+98 21 5565 8500
Fax
+98 21 5564 8189
Email
h-hosami@sina.tums.ac.ir
Web page address
https://baharloo.tums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Nafiseh Sadat Alizadeh
Position
clinical pharmacologist
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Baharloo Hospital- Behdari street- rail way square
City
Tehran
Province
Tehran
Postal code
139973111
Phone
+98 21 5565 8500
Fax
+98 21 5564 8189
Email
nafisehalizadeh@yahoo.com
Web page address
https://baharloo.tums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Nafiseh Sadat Alizadeh
Position
clinical pharmacologist
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Baharloo Hospital- Behdari Avenue- Rah Ahan square
City
Tehran
Province
Tehran
Postal code
139973111
Phone
+98 21 5565 8500
Fax
+98 21 5564 8189
Email
nafisehalizadeh@yahoo.com
Web page address
http://baharloo.tums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
there is no more data
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...